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The p53 tumor suppressor protein is stabilized in re-
sponse to ionizing radiation and accumulates in the nu-
cleus. Stabilization is thought to involve disruption of
the interaction between the p53 protein and Mdm2,
which targets p53 for degradation. Here we show that
the direct association between a p53 N-terminal peptide
and Mdm2 is disrupted by phosphorylation of the pep-
tide on Thr18 but not by phosphorylation at other N-
terminal sites, including Ser15 and Ser37. Thr18 was
phosphorylated in vitro by casein kinase (CK1); this
process required the prior phosphorylation of Ser15.
Thr18 was phosphorylated in vivo in response to DNA
damage, and such phosphorylation required Ser15. Our
results suggest that stabilization of p53 after ionizing
radiation may result, in part, from an inhibition of
Mdm2 binding through a phosphorylation-phosphoryla-
tion cascade involving DNA damage-activated phospho-
rylation of p53 Ser15 followed by phosphorylation of
Thr18.
The p53 tumor suppressor protein is a critical regulator of
cell cycle progression that responds to DNA damage and cer-
tain other cellular stresses by arresting cell cycle progression or
by inducing apoptosis (1–3). These responses are important for
preserving the integrity of the genome of a cell, thus preventing
the transformation of a normal cell into a tumor cell. p53
normally is a short-lived protein that is maintained at low
levels in unstressed cells. After cells are exposed to DNA-
damaging agents, nucleotide depletion, or hypoxia, the p53
protein is transiently stabilized and accumulates in the nu-
cleus. DNA damage also activates p53 as a transcription factor,
which in turn induces or represses the transcription of several
genes, including WAF1 and MDM2, that regulate cell cycle
progression. Both stabilization of the p53 protein and activa-
tion of its sequence-specific DNA binding ability are widely
believed to be mediated, at least in part, by post-translational
modifications to the p53 protein. p53 is phosphorylated on
several sites in its N-terminal transactivation domain as well
as on several sites in the C-terminal tetramerization/regula-
tory domain (4), and recent studies have shown that serines 15,
33, and 37 become phosphorylated after cells are exposed either
to ionizing radiation (IR)1 or to UV light (5–7). In undamaged
cells, p53 levels are low because the protein is rapidly degraded
through a ubiquitin-mediated pathway (8, 9) that is mediated
by the Mdm2, a protein that binds to the N terminus of p53 (10,
11) and serves as an ubiquitin ligase (12). Recently, it was
reported that incubating p53 with DNA-PK, a protein kinase
activated by DNA strand breaks that phosphorylates human
p53 in vitro on both Ser15 and Ser37 (13), inhibited the binding
of p53 to Mdm2 (5, 12, 14). Thus, phosphorylation of these sites
in vivo may stabilize p53 by preventing Mdm2 binding.
To test this prediction, we measured the binding constant for
peptides corresponding to the N terminus of p53 and a human
Mdm2 fragment that binds p53 (11). Surprisingly, phosphoryl-
ation of Ser15, of Ser37, or of both residues had only a small
effect on the binding constant. Hence, either the inhibition of
p53-Mdm2 binding by DNA-PK was not due to its phosphoryl-
ation of p53 or the observed effects were an indirect conse-
quence of that phosphorylation. Here, we show that the latter
explanation may be correct. We demonstrate that phosphoryl-
ation of Thr18 of p53 by casein kinase 1 (CK1) or a CK1-like
activity is activated by phosphorylation of Ser15 and that this
phosphorylation can account, in part, for the inhibition of p53
binding by Mdm2 observed after exposing cells to ionizing
radiation.
EXPERIMENTAL PROCEDURES
Cells and Cell Transfections—A549 (ATCC CCL-185), a human lung
carcinoma cell line that expresses wild-type p53, was obtained from the
American Type Culture Collection (Manassas, VA); NCI-H1299 (ATCC
CRL-5803), a human lung carcinoma cell line that is null for both p53
alleles (15), was obtained from A. Fornace, Jr. (NCI, National Institutes
of Health). Cells were grown to 50–70% confluency in Dulbecco’s mod-
ified minimal essential medium supplemented with 10% fetal bovine
serum and 100 nM glutamine in 150-mm dishes. Cultures were trans-
fected with 10 mg of DNA/plate by the LipofectAMINE Plus procedure
as described by the manufacturer (Life Technologies, Inc.). One day
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after transfection, cultures were exposed to 8 gray by using a Shepherd
Mark I 137Cs irradiator or treated with ALLN, a proteasome inhibitor,
as described (7). After the times indicated (see Fig. 3), cultures were
harvested and processed for immunoprecipitation and immunoblotting.
Phosphorylation-specific p53 Antibodies—Antibodies specific for p53
phosphorylated at Thr18 or Ser20 were prepared as described (7). Briefly, the
PabSer(P)20 and PabThr(P)18 antibodies were made by immunizing rabbits
with the p53 phosphopeptides Ac-15–26(20P)C (i.e. Ac-Ser-Gln-Glu-Thr-
Phe-Ser(P)-Asp-Leu-Trp-Lys-Leu-Leu-Cys-NH2) or Ac-13–24(15, 18P)C (i.e.
Ac-Pro-Leu-Ser(P)-Gln-Glu-Thr(P)-Phe-Ser-Asp-Leu-Trp-Lys-Cys-NH2)
coupled to keyhole limpet hemocyanin, respectively. Phosphorylation site-
specific antibodies were affinity purified from the resulting serum using the
corresponding phosphorylated peptides attached to SulfoLink (Pierce). In
the case of PabThr(P)18, the antibody was depleted of Ser15(P) cross-react-
ing activity by also passing the preparation through a column of Ac-p53(13–
24)(15P)C attached to SulfoLink. The antibody to p53 phosphorylated at
Ser15 was made by immunizing a rabbit with the peptide human p53(13–
19(15F2Pab))A(13–19(15F2Pab))AC coupled to keyhole limpet hemocyanin,
i.e. PL(F2Pab)QETAPL(F2Pab)QETAC-KLH. F2Pab is a phosphoserine mi-
metic (16) and was incorporated as the BOC-F2Pab(OEt2-OH) derivative.
Phosphoserine 15-specific antibodies were purified using the natural phos-
phopeptide (p53(Ac-11–22(15P)Cys)-SulfoLink conjugate.
Synthetic Phosphopeptides—Peptides were synthesized by the solid
phase method with Fmoc chemistry using an Applied Biosystems (Fos-
ter City, CA) 430A peptide synthesizer. Phosphoserine was incorpo-
rated as Fmoc-Ser(PO(OBzl)OH)-OH, and phosphothreonine was incor-
porated as Fmoc-Thr(PO(OBzl)OH)-OH (Novabiochem, San Diego, CA).
Peptide p53(15–29) was labeled with 5-carboxyfluorescein, succinimidyl
ester (Pierce) on the resin. Peptides were cleaved from the resin, and
side chain protecting groups were removed by incubating in reagent K
(trifluoroacetic acid:phenol:thioanisole:H2O:EDT, 82.5:5:5:5:2.5) for 3 h
at room temperature. The p53(1–39) peptides were purified by high
pressure liquid chromatography on a pH-stable Vydac C-8 column (Hes-
peria, CA) with 0.2% hexafluoroacetone-NH4OH, pH 7.0, acetonitrile.
The masses of peptides were confirmed by electrospray ionization mass
spectrometry on a Finnigan MAT SSQ 7000 (Finnigan MAT, San Jose,
CA).
Measurement of p53-Mdm2 Dissociation Constants—The dissocia-
tion constants (Kd) for unlabeled p53 peptides from the Mdm2 fragment
were determined by a competition assay with fluorescein-labeled
p53(15–29) in 25 mM MES, pH6.8, 100 mM NaCl, 0.5 mM EDTA con-
taining 0.1 mg/ml bovine serum albumin at 4°C (17, 18). Fluorescence
anisotropy was measured in a PanVera Beacon 2000 instrument with
temperature control (PanVera Corporation, Madison, WI). Binding con-
stants were determined as follows. The binding constant of the labeled
peptide was first determined by titrating 50 nM fluorescein-labeled
p53(15–29) with increasing amounts of Mdm2(17–125) and measuring
the fluorescence anisotropy at each concentration. In separate experi-
ments, 50 nM of fluorescein labeled p53(15–29) was mixed with several
different concentrations of unlabeled peptides, and these mixtures were
titrated with the Mdm2 fragment. Fluorescence anisotropy was re-
corded at each concentration.
The binding constant of the fluoresceinated p53(15–29) peptide was
determined by fitting to a single site binding equation using either
SigmaPlot (SPSS Inc., San Rafael, CA) or a BASIC program written by
the authors. For the competition assays, binding isotherms at three
concentrations were simultaneously fitted by a global-fit program de-
veloped by the authors to the following equations.
Aobs 5 Af 1 ~Ac 2 Af!@P*M#/@P*#T (Eq. 1)
@P*M# 5 K*@P*#TX/~1 1 K* z X! (Eq. 2)
X 5 ~~~1 1 K@P#T 2 K@M#T!2
1 4 z K@M#T!1/2 2 ~1 1 K@P#T 2 K@M#T!!/2K (Eq. 3)
Af is the anisotropy of the free labeled peptide, Ac is the anisotropy of
the labeled peptide-Mdm2 complex, Aobs is the observed anisotropy, K*
is the association constant of the labeled peptide with the Mdm2 frag-
ment, K is the association constant of the unlabeled peptide with the
Mdm2 fragment, [P*]T is the total concentration of labeled peptide, [P]T
is the total concentration of unlabeled competing peptide, [P*M] is the
concentration of the labeled peptide-Mdm2 complex, and [M]T is the
total concentration of Mdm2 fragment. These equations were derived
from the Weber average formula (19) and the mass action law, assum-
ing that [M]f 1 [PM] .. [P*M], where [M]f is the free Mdm2 fragment
concentration and [PM] is the concentration of the unlabeled peptide-
Mdm2 fragment complex. Because of the concentration of the labeled
peptide used and the affinity constants, such an assumption is fully
justified.
Kinase Reactions—The p53(Ac-1–24) peptides at 200 mM were incu-
bated at 30 °C for 30 min with recombinant CK1-d (New England
BioLabs) in 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 5 mM dithiothreitol,
and 200 mM ATP containing [g-32P]ATP. The 32P-labeled peptides were
separated by chromatography in n-butanol:prydine:acetic acid:water
(3:2:1:4) on cellulose TLC plates (Merck). A recombinant fusion protein,
N47 (20), containing residues 2–47 of human p53, at 38 mM was incu-
bated at 30 °C for 30 min with DNA-PK (Promega) in 50 mM Hepes, pH
7.5, 50 mM KCl, 10 mM MgCl2, 1 mM dithiothreitol, 200 mM ATP, and 10
mg/ml calf thymus DNA. The reactants then were diluted into an equal
volume of a CK1-d reaction as described above, but without peptide, and
incubation was continued for an additional 30 min. Phosphoamino acid
analysis was performed as described (21).
Detection of p53 Phosphorylation by Western Immunoblotting—Cell
extracts were prepared, and Western immunoblots were performed
essentially as described (7); however, in place of immunoprecipitation
with protein G-Sepharose, p53 was collected by centrifugation with a
1:1 mixture of PAb1801- and DO-1-agarose beads (Santa Cruz Biotech-
nology, Inc.). 5 mg of each antibody conjugate was used for 1300 mg of
extract protein; after incubation for 2 h at 4 °C, the beads were washed
five times by centrifugation. To avoid possible interference by the IgG
heavy chain, the reducing agent was omitted from the SDS-polyacryl-
amide gel electrophoresis sample buffer.
RESULTS
Interaction of p53(1–39) and Mdm2(17–125)—To examine
directly the effect of N-terminal phosphorylation on the inter-
action of p53 and Mdm2, we determined the dissociation con-
stants for various phosphorylated p53(1–39) peptides with
Mdm2(17–125) by measuring the changes in fluorescence ani-
sotropy of fluorescein-labeled p53(15–29) complexed with
Mdm2(17–125) in response to added p53(1–39) (Fig. 1 and
Table I). Different amounts of Mdm2 were added to mixtures of
the fluorescein-labeled probe and p53(1–39) or p53(1–39) phos-
phorylated at different positions. The dissociation constant for
each peptide with Mdm2 then was determined by fitting the
curves using a mathematical model (see “Experimental Proce-
dures”). Unphosphorylated p53(1–39) bound Mdm2 with an
apparent dissociation constant of 70 6 20 nM (Fig. 1A), whereas
p53(1–39) with Ala-Ala replacing Leu22-Trp23 exhibited no
measurable binding (Fig. 1D). Surprisingly, p53(1–39) phos-
phorylated on Ser15 (Fig. 1B), on Ser37 or on both residues had
dissociation constants that were only slightly higher (60–260
nM) on average than the unphosphorylated peptide (Table I).
Phosphorylation of the p53 N-terminal peptide on Ser9, Ser20,
Ser33, or Ser15 and Ser20 also only slightly affected the inter-
action of p53 and Mdm2. In contrast, phosphorylation of Thr18
or of Thr18 and Ser15 (Fig. 1C) dramatically reduced the asso-
ciation (;30–50-fold). Contrary to previous reports, these data
suggest that phosphorylation of p53 at Ser15 and Ser37 does not
directly inhibit formation of the p53-Mdm2 complex; rather,
phosphorylation of Thr18, which stabilizes the association with
Mdm2 through hydrogen bonding of the threonine hydroxyl
group (11), appears to be crucial.
Phosphorylation of Thr18 in Vivo in Response to Ionizing
Radiation—To explore the question of its phosphorylation, we
prepared an antibody that specifically recognizes p53 only
when it is phosphorylated on Thr18; we also made antibodies
that recognize p53 only when it is phosphorylated on Ser15 or
on Ser20. The specificities of these antibodies for p53 phospho-
rylated at the respective sites were confirmed by peptide en-
zyme-linked immunosorbent assays and/or by peptide dot-blot
assays as reported recently for other p53 phosphorylation-spe-
cific antibodies (7). Fig. 2 shows the specificity of the p53
phospho-Thr18 antiserum as determined by enzyme-linked im-
munosorbent assay. The antiserum recognized the p53(1–39)
peptide phosphorylated on Thr18 alone or on Thr18 and Ser15. It
also recognized a p53(Ac-13–24) peptide phosphorylated at
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Thr18 and Ser20, although not so well. It did not recognize the
unphosphorylated p53(1–39) peptide, the peptide with Ser15
changed to alanine, the p53(1–39) peptide phosphorylated at
Ser15, the peptide phosphorylated at both Ser15 and Ser20, nor
several other control peptides; however, the antibody did rec-
ognize the p53(1–39) peptide with Ser15 changed to alanine and
Thr18 phosphorylated (data not shown). These data show that
the PAbThr(P)18 antiserum specifically recognizes p53 when
phosphorylated on Thr18 but not on other N-terminal p53 phos-
phorylation sites; its recognition is not abrogated by phospho-
rylation at Ser15 or Ser20 nor by changing Ser15 to another
amino acid.
Fig. 3 shows that p53 Thr18 was not detectably phosphoryl-
ated in unirradiated A549 cells nor in cells treated with the
proteasome inhibitor ALLN, which stabilizes p53 (22), as seen
with DO-1, a monoclonal antibody specific for the N terminus of
p53. However, after cells were exposed to 8 gray of g-irradia-
tion, a dramatic, transient phosphorylation of Thr18 was ob-
served by 45 min that peaked 2 h after exposure and disap-
peared between 8 and 24 h. Ser20 also was phosphorylated after
IR with similar initial kinetics, but it remained phosphorylated
at 24 h. As shown previously (5, 6), phosphorylation of Ser15 is
rapidly induced by IR and was seen within 45 min of exposure;
phosphorylation peaked at 2 h and then slowly declined (Fig.
3). Similar to Thr18, Ser15, or Ser20 were not phosphorylated in
unirradiated A549 cells nor in cells treated with ALLN. These
results show that Thr18 and Ser20 at the N terminus of p53, like
Ser15, Ser33, and Ser37, are phosphorylated in response to DNA
damage. We caution, however, that in WS1, a human embry-
onic skin fibroblast cell line (ATTC CRL-1502), and in normal
adult human fibroblasts, phosphorylation of Thr18 appeared
significantly weaker than in A549 cells even though good phos-
phorylation at Ser15 was observed after exposure to ionizing
radiation (data not shown). This finding suggests that the role
of Thr18 phosphorylation may be cell type-specific.
Thr18 Phosphorylation in Vitro by Casein Kinase 1—The N
terminus of mouse p53 is phosphorylated by CK1 (23, 24), a
ubiquitously expressed protein kinase, the specificity of which
can be directed to specific serines and threonines by phospho-
rylation at the 23 position (25–27). CK1 also prefers a hydro-
phobic residue at the 11 position. Thr18 lies three residues
downstream of Ser15 and is followed by Phe19. To ascertain
whether CK1 can phosphorylate Thr18, we incubated recombi-
nant human CK1-d with p53(Ac-1–24) or p53(Ac-1–24) phos-
phorylated at Ser15, Ser9, and Ser15, or at Ser15 with Thr18,
Ser6, Ser9, or Thr18 and Ser20 changed to Ala (Fig. 4A). Little or
no phosphorylation was observed unless Ser15 was phosphoryl-
ated and Thr18 was present, indicating that in vitro prior
phosphorylation of Ser15 specifically activates phosphorylation
of Thr18 by CK1. Phosphoamino acid analysis confirmed that
Thr18 is the major target for phosphorylation by CK1 (Fig. 4B).
Phosphorylation of Thr18 also was potentiated by prior phos-
phorylation of an N-terminal p53 fusion protein with DNA-PK
(Fig. 4C); without phosphorylation by DNA-PK, Thr18 was not
phosphorylated by CK1, as shown by immunoblot analysis with
the PAbThr(P)18 antibody.
Phosphorylation of Thr18 in Vivo Requires Ser15—If CK1 is
responsible for phosphorylating Thr18 in vivo, then this process
also should depend on the phosphorylation of Ser15. To address
this question, we transfected H1299 lung carcinoma cells,
which do not express p53 (15), with p53 expression vectors for
wild-type human p53 or p53 mutated to change Ser15 or Ser37
to Ala (28). Cells were then either irradiated or not, and ex-
tracts were processed for immunoblot analysis with the
PAbThr(P)18 antibody. Phosphorylation of Thr18 clearly was
FIG. 1. Effect of N-terminal phosphorylation on the interac-
tion of p53(1–39) with Mdm2(17–125). The anisotropy of fluorescein-
p53(15–29) was determined as a function of Mdm2(17–125) concentra-
tion for three different concentrations of competitor p53(1–39) peptide
that was unphosphorylated (A), phosphorylated on Ser15 only (B), phos-
phorylated on Ser15 and Thr18 (C), or mutated to change both Leu22 and
Try23 to Ala (D), as described under “Experimental Procedures.” Com-
petitor peptide concentrations for A and B were 0.3 mM (l), 1.0 mM (),
and 2.0 mM (l ); competitor peptide concentrations for C were 1 mM (l),
2 mM (), and 5 mM (l ); competitor peptide concentrations for D were 5
mM (l), 10 mM (), and 15 mM (l ). Data points were determined in
triplicate and fitted to a set of equations as described under “Experi-
mental Procedures” to determine the apparent dissociation constant
(Kd) for the competitor peptide-Mdm2(17–125) complex. Similar exper-
iments were performed to determine dissociation constants for other
peptides described in Table I.
TABLE I
Binding affinity of p53(1–39) peptides with Mdm2(17–125)
Peptidea Kd
b 6S.D.c
nM nM
1–39 70 20
1–39(9P) 120 60
1–39(15P) 170 20
1–39(18P) 3400 660
1–39(20P) 110 40
1–39(33P) 210 140
1–39(37P) 260 90
1–39(15,18P) 2400 200
1–39(15,20P) 70 20
1–39(15,37P) 60 30
1–39(22,23Ala)d .190,000 NA
p73(1–37)e 430 ND
a Human p53(1–39) peptides phosphorylated at the site or sites indi-
cated.
b The apparent dissociation constants were determined from meas-
urements of the fluorescence anisotropy (see “Experimental Proce-
dures”).
c Each value is the average of at least three determinations. NA, not
applicable; ND, not determined.
d Residues Leu22 and Trp23 in the p53(1–39) peptide were changed to
Ala.
e First 37 residues from human p73 (GenBank™ accession number
3414961, MAQSTATSPD GGTTFEHLWS SLEPDSTYFD LPQSSRG).
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observed in H1299 cells transfected with wild-type p53 or with
p53 that had Ser37 changed to Ala but not in cells transfected
with p53 that had Ser15 changed to Ala (Fig. 5). In contrast,
Ser20 was phosphorylated in both mutants. No phosphorylation
signal was observed from cells transfected with the vector
alone. In contrast to endogenous p53 in A549 cells (Fig. 3),
phosphorylation of p53 at Ser20 and Thr18 in transfected cells
was only stimulated by and not dependent on the intentionally
applied DNA damage (Fig. 5). We believe that in this case
phosphorylation may be induced by the process of transfection
or by DNA breaks present in the transfected DNA (29).
DISCUSSION
In vitro, Ser15 can be phosphorylated by DNA-PK (13) and
ATM (20, 30, 31), a related protein kinase that is missing or
defective in people with ataxia telangiectasia (32). In vivo effi-
cient phosphorylation of Ser15 after exposing cells to IR re-
quires a functional ATM gene (6), and in ATM-deficient cells,
the accumulation of p53 in response to IR also is delayed (33),
suggesting that phosphorylation of Ser15 is important for sta-
bilizing p53. An important mechanism that regulates p53 sta-
bility is its binding to Mdm2, which targets p53 for ubiquitin-
mediated degradation. In contrast to other reports (5, 12, 14,
34), our data suggest that Ser15 phosphorylation indirectly
affects the association of p53 with Mdm2 rather than directly
(Fig. 6). Compared with the unphosphorylated peptide, the
association of p53 N-terminal peptides phosphorylated at
Ser15, Ser37, or both, with Mdm2(17–125) was barely reduced.
Importantly, however, this association was dramatically inhib-
ited by phosphorylation at Thr18 (Table I). The crystal struc-
ture of Mdm2(17–125) with the N terminus of p53 shows that
p53 residues 18–26 form an amphipathic helix that fits into a
deep hydrophobic groove in the Mdm2 structure (11). Hydrogen
bonds made by the side chain hydroxyl of Thr18 with a back-
bone amide and the side chain carboxyl group of Asp21 of p53
contribute to stabilizing the helical structure of this segment.
Phosphorylation of Thr18 would eliminate these bonds and
introduce a charge-charge repulsion with Asp21 that would
further destabilize the p53-Mdm2 interaction. In contrast,
Ser15 and Ser37 lie outside the region of direct contact deter-
mined from the crystal structure. Thus, structural consider-
ations support a role for Thr18 phosphorylation in inhibiting
the association between p53 and Mdm2. While this report was
in preparation, Bo¨ttger et al. (35) reported that phosphoryla-
tion of Thr18 or replacement of this threonine by amino acids
other than serine substantially decreased the interaction of p53
N-terminal peptides with GST-Mdm2, in agreement with the
results reported here. Moreover, Craig et al. (34) recently re-
ported that monoclonal antibodies specific for phosphorylated
Thr18 detected p53 in human breast cancers with elevated p53.
They also found that a peptide phosphorylated at Thr18 inhib-
ited p53 binding by Mdm2.
CK1-d and CK1-e are closely related, ubiquitously expressed
mammalian homologs of budding yeast Hrr25, a nuclear Ser/
Thr protein kinase that was isolated in a screen for mutants
sensitive to double-stranded breaks (36–38). Yeast HRR25 mu-
tants are defective in the transcriptional induction of a subset
of DNA damage-inducible genes that require Swi6, a transcrip-
tion factor phosphorylated by Hrr25 in vitro (39). Murine CK1
phosphorylates several residues at the N terminus of mouse
p53 (23, 24), but these residues are not completely conserved in
human p53, and our attempts to phosphorylate the N terminus
of unmodified human p53 with recombinant CK1-d were un-
successful (Fig. 4). In contrast to unmodified p53, p53(1–24)
phosphorylated at Ser15 but not Ser9, and recombinant p53(2–
47) phosphorylated at Ser15 and Ser37 with DNA-PK were
efficiently phosphorylated by CK1 in vitro. These results are in
FIG. 2. Specificity of the
PAbThr(P)18 antiserum. An affinity-
purified rabbit polyclonal antibody spe-
cific for p53 phosphorylated at Thr18 was
prepared as described under “Experimen-
tal Procedures,” and the antibody was
evaluated by standard enzyme-linked im-
munosorbent assay using synthetically
prepared p53 peptides. These peptides in-
cluded human p53(1–39), unphosphoryl-
ated (M); p53(1–39) phosphorylated at
Ser15 (L); p53(1–39) phosphorylated at
Thr18 (l ); p53(1–39) phosphorylated at
Ser15 and Thr18 (); p53(1–39) phospho-
rylated at Ser15 and Ser20 (); p53(13–24)
unphosphorylated and acetylated at the
N terminus (); p53(Ac13–24) phospho-
rylated at Ser15 and Thr18 (f); p53(Ac13–
24) phosphorylated at Thr18 and Ser20
(). This antiserum did not recognize
p53(1–39) with Ser15 changed to alanine
but did recognize p53(1–39) with Ser15
changed to alanine and Thr18 phosphoryl-
ated (data not shown).
FIG. 3. Phosphorylation of p53 at Ser15, Thr18, and Ser20 in
response to IR. A549 cells were irradiated with 8 gray or treated with
20 mM ALLN, and cell extracts were prepared at the indicated times.
After precipitation with PAb1801- and DO-1-agarose beads, p53 was
analyzed by Western immunoblotting with the antibodies indicated at
the left. DO-1 recognizes an epitope in the p53 transactivation domain;
ALLN is an inhibitor of proteasome-mediated degradation. PAb-
Ser(P)15, PAbThr(P)18, and PAbSer(P)20 recognize human p53 only
when phosphorylated on Ser15, Thr18, or Ser20, respectively, as de-
scribed under “Experimental Procedures.”
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keeping with the known ability of phosphoserine at the 23
position to potentiate phosphorylation by CK1 (25). Phospho-
rylation of Ser15 is an early event in response to IR (5, 6) (Fig.
3), and CK1 isoforms are ubiquitously expressed; thus, CK1 is
a likely candidate for phosphorylating p53 Thr18 in vivo. Con-
sistent with this possibility, we found that phosphorylation of
Thr18 in response to DNA damage required the presence of
Ser15. Curiously, this experiment also revealed that mutation
of Ser37 to alanine enhanced the level of phosphorylation at
Thr18, Ser15, and Ser20 (Fig. 5). The reason for this enhance-
ment is not known but presumably reflects changes in sub-
strate recognition for the kinases or phosphatases that control
these phosphorylations and that are either dependent on Ser37
itself or modulated by its phosphorylation. This and other
recent observations indicate that there is a complex interplay
between different N-terminal phosphorylation sites. For exam-
ple, we recently reported that changing Ser33 to alanine unex-
pectedly decreased phosphorylation levels of Ser15 and Ser37
(29).
Phosphorylation of Thr18 certainly is not the only mechanism
for stabilizing p53. Phosphorylation of Thr18 after exposure to
IR is transient, peaking at about 2 h (Fig. 3), and this time
course is not completely coincident with p53 accumulation.
Recently, Ashcroft et al. (40) and Blattner et al. (41) reported
that p53 mutated to change several phosphorylation sites in-
cluding Thr18 to alanine is still stabilized after exposure to
DNA damage-inducing agents. We therefore postulate that
DNA damage-induced modifications to Mdm2 (42) or other
components of the targeting system may contribute to stabiliz-
ing p53. Furthermore, transfection of HCT-116 p532/2 cells
with increasing amounts of Mdm2 expressing plasmid did not
differentially affect the stability of wild-type p53 compared
with p53-S15A or p53-T18A (data not shown). Thus, under
these conditions, phosphorylation of Thr18 is not the dominant
regulator of p53 stability. Given the central role of p53 in
integrating stress-related signals and the apparent multiple
mechanisms of activating p53 sequence-specific DNA binding
(2, 3), the existence of redundant mechanisms for stabilizing
p53 would not be surprising. In other cell types or under other
FIG. 4. Phosphorylation of p53 N-terminal fragments by CK1.
A, recombinant CK1-d and [g-32P]ATP were incubated with p53(Ac-1–
24) or the indicated related peptide; the reaction products were sepa-
rated by thin layer chromatography, and the phosphorylated products
were detected by autoradiography. The position of the peptides are
indicated (Ac-1–24). B, two-dimensional phosphoamino acid analysis of
the p53(Ac-1–24(15P) peptide after incubation with CK1-d. The posi-
tions of inorganic phosphate (Pi), phosphoserine (Ser(P)), phospho-
threonine (Thr(P)), and the origin (3) are shown. C, a human p53(2–
46)-human Oct-1 Pou-domain fusion protein was incubated with DNA-
PK, CK1, or both, and the products were analyzed by immunoblotting
with DO-1 or phosphorylation-specific antibodies as indicated.
FIG. 5. Phosphorylation of p53 Thr18 requires Ser15. H1299 cells
were transfected with 10 mg/plate of vector (vec), pC53-SN3, which
expresses wild-type human p53 (43) or p53-S15A or p53-S37A (28). One
day after transfection one set of cultures were exposed to 8 gray of IR;
both sets were harvested for Western immunoblot analysis 2 h later.
The antibodies used to detect p53 are indicated at the left.
FIG. 6. Model for inhibition of Mdm2 binding to p53 by Ser15-
mediated phosphorylation of Thr18 by CK1. Human p53 becomes
rapidly phosphorylated after cells are exposed to ionizing radiation
(Fig. 3), possibly by ATM (20, 30). Phosphorylation of Ser15 allows CK1
or a CK1-like enzyme to phosphorylate Thr18. Phosphorylation of Thr18
inhibits binding by Mdm2, thus preventing Mdm2-mediated degrada-
tion. DNA damage-induced phosphorylation of Ser15, Thr18, or of other
residues also may potentiate or inhibit interaction of p53 with other
proteins that bind to its N terminus including RPA, TFIIH, JNK, and
p300.
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circumstances, phosphorylation of Thr18 could play a more
important role. Phosphorylation of Thr18 and other sites at the
N terminus of p53 also may regulate the interaction of p53 with
other cellular proteins, such as CBP/p300, TFIIH, the TAFs,
RPA, and JNK (Fig. 6), and in many cells, the regulation of
such interactions may be more important. Investigations of
these possibilities are in progress.
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